华法林长期用于缺血性脑卒中抗凝的安全性分析  

Safety Analysis of Long-term Use of Warfarin for Anticoagulation in Ischemic Stroke

作　　者：闵晓梅 刘美洁[2] MIN Xiaomei;LIU Meijie(Department of Neurology,Zhongyi Northeast International Hospital,Shenyang 110000,Liaoning,China;Department of Neurology,Liaoning Provincial People’s Hospital,Shenyang 110000,Liaoning,China)

机构地区：[1]中一东北国际医院神经内科,辽宁沈阳110000 [2]辽宁省人民医院神经内科,辽宁沈阳110000

出　　处：《中国药物滥用防治杂志》2021年第5期700-703,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨华法林长期用于缺血性脑卒中抗凝的安全性。方法:回顾性分析2017年2月—2019年2月我院收治的缺血性脑卒中患者100例,按照随机数表法分为对照组和研究组,各50例。对照组采用常规抗凝治疗,研究组采用华法林长期抗凝治疗,随访2年比较两组临床治疗效果、并发症发生情况、患者依从率、凝血指标及CHA2DS2-VASc评分与HAS-BLED评分。结果:研究组治疗总有效率为98.00%,高于对照组的80.00%(P<0.05)。研究组并发症总发生率为4.00%,低于对照组的18.00%(P<0.05)。研究组总依从率为96.00%,高于对照组的76.00%(P<0.05)。研究组INR、PT、APTT、TT优于优于对照组(P<0.05)。两组CHA2DS2-VASc评分比较,差异无统计学意义(P>0.05),而研究组HAS-BLED评分低于对照组(P<0.05)。结论:华法林长期用于缺血性脑卒中抗凝治疗效果较为明显,可有效改善患者凝血功能,且并发症较少,患者依从率高,具有应用安全性及有效性。Objective:To explore the safety of warfarin used for long-term anticoagulation in ischemic stroke.Methods:A retrospective analysis of 100 patients with ischemic stroke admitted to our hospital from February 2017 to February 2019 were divided into control group and study group according to the random number table method,with 50 cases in each group.The control group was treated with conventional anticoagulation therapy,and the study group was treated with warfarin for long-term anticoagulation.The two groups were followed up for 2 years to compare the clinical treatment effects,complications,patient compliance,coagulation indexes,CHA2DS2-VASc score and HAS-BLED score.Results:The total effective rate of treatment in the study group was 98.00%,which was higher than 80.00%in the control group(P<0.05).The total incidence of complications in the study group was 4.00%,which was lower than 18.00%in the control group(P<0.05).The total compliance rate of the study group was 96.00%,which was higher than the 76.00%of the control group(P<0.05).The INR,PT,APTT,and TT of the study group were better than those of the control group(P<0.05).There was no signifififi cant difference in CHA2DS2-VASc scores between the two groups(P>0.05),while the HAS-BLED scores of the study group were lower than those of the control group(P<0.05).Conclusion:The long-term use of warfarin in anticoagulant treatment of ischemic stroke is more effective,which can effectively improve the coagulation function of patients with fewer complications,high patient compliance rate,and has application safety and effectiveness.

关 键 词：华法林 长期 缺血性脑卒中 抗凝 安全性 

分 类 号：R969.3[医药卫生—药理学]